Sanofi India Limited (SANOFI.NS)
INR 6221.5
(0.23%)
INR 6221.5
(0.23%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 12.19 Billion INR | 4.1% |
| 2022 | 7.34 Billion INR | -3.88% |
| 2021 | 7.63 Billion INR | 5.54% |
| 2020 | 7.23 Billion INR | 9.39% |
| 2019 | 6.61 Billion INR | 8.02% |
| 2018 | 6.12 Billion INR | 18.43% |
| 2017 | 5.17 Billion INR | 10.61% |
| 2016 | 4.67 Billion INR | 17.38% |
| 2015 | 3.98 Billion INR | 30.46% |
| 2014 | 3.05 Billion INR | -14.61% |
| 2013 | 3.57 Billion INR | 35.84% |
| 2012 | 2.63 Billion INR | -7.74% |
| 2011 | 2.85 Billion INR | 20.41% |
| 2010 | 2.36 Billion INR | -2.02% |
| 2009 | 2.41 Billion INR | -7.21% |
| 2008 | 2.6 Billion INR | 16.82% |
| 2007 | 2.23 Billion INR | -10.99% |
| 2006 | 2.5 Billion INR | 5.87% |
| 2005 | 2.36 Billion INR | 7.84% |
| 2004 | 2.19 Billion INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 2.08 Billion INR | 17.89% |
| 2024 Q2 | 1.06 Billion INR | -48.92% |
| 2023 Q1 | 2.46 Billion INR | 39.06% |
| 2023 FY | 7.64 Billion INR | 4.1% |
| 2023 Q2 | 1.84 Billion INR | -25.16% |
| 2023 Q4 | 1.77 Billion INR | -15.66% |
| 2023 Q3 | 2.1 Billion INR | 14.12% |
| 2022 FY | 7.34 Billion INR | -3.88% |
| 2022 Q2 | 1.66 Billion INR | -20.1% |
| 2022 Q3 | 1.82 Billion INR | 10.05% |
| 2022 Q4 | 1.76 Billion INR | -3.28% |
| 2022 Q1 | 2.08 Billion INR | 65.08% |
| 2021 Q1 | 1.95 Billion INR | 17.93% |
| 2021 Q3 | 1.99 Billion INR | -18.06% |
| 2021 Q4 | 1.26 Billion INR | -36.75% |
| 2021 Q2 | 2.43 Billion INR | 24.48% |
| 2021 FY | 7.63 Billion INR | 5.54% |
| 2020 FY | 7.23 Billion INR | 9.39% |
| 2020 Q4 | 1.65 Billion INR | -11.21% |
| 2020 Q3 | 1.86 Billion INR | 0.32% |
| 2020 Q2 | 1.85 Billion INR | 0.22% |
| 2020 Q1 | 1.85 Billion INR | 1.15% |
| 2019 Q4 | 1.83 Billion INR | 6.57% |
| 2019 Q1 | 3.02 Billion INR | 130.19% |
| 2019 Q2 | 1.55 Billion INR | -48.73% |
| 2019 Q3 | 1.72 Billion INR | 10.89% |
| 2019 FY | 6.61 Billion INR | 8.02% |
| 2018 Q2 | 1.59 Billion INR | 21.5% |
| 2018 Q4 | 1.31 Billion INR | -29.87% |
| 2018 FY | 6.12 Billion INR | 18.43% |
| 2018 Q1 | 1.31 Billion INR | 3.7% |
| 2018 Q3 | 1.87 Billion INR | 17.26% |
| 2017 Q3 | 1.78 Billion INR | 51.14% |
| 2017 Q2 | 1.18 Billion INR | 28.45% |
| 2017 Q1 | 921 Million INR | 13.28% |
| 2017 FY | 5.17 Billion INR | 10.61% |
| 2017 Q4 | 1.26 Billion INR | -29.03% |
| 2016 Q4 | 813 Million INR | -37.22% |
| 2016 FY | 4.67 Billion INR | 17.38% |
| 2016 Q3 | 1.29 Billion INR | -2.04% |
| 2016 Q2 | 1.32 Billion INR | 6.1% |
| 2016 Q1 | 1.24 Billion INR | 29.93% |
| 2015 Q3 | 1.22 Billion INR | 18.85% |
| 2015 FY | 3.98 Billion INR | 30.46% |
| 2015 Q4 | 959 Million INR | -21.59% |
| 2015 Q1 | 764 Million INR | 63.81% |
| 2015 Q2 | 1.02 Billion INR | 34.69% |
| 2014 Q2 | 874 Million INR | 11.34% |
| 2014 Q3 | 940 Million INR | 7.55% |
| 2014 FY | 3.05 Billion INR | -14.61% |
| 2014 Q4 | 466.4 Million INR | -50.38% |
| 2014 Q1 | 785 Million INR | -22.81% |
| 2013 Q4 | 1.01 Billion INR | -12.7% |
| 2013 Q2 | 792 Million INR | 20.18% |
| 2013 Q1 | 659 Million INR | -1.07% |
| 2013 FY | 3.57 Billion INR | 35.84% |
| 2013 Q3 | 1.16 Billion INR | 47.1% |
| 2012 Q3 | 764 Million INR | 26.7% |
| 2012 Q4 | 666.1 Million INR | -12.81% |
| 2012 Q2 | 603 Million INR | 0.84% |
| 2012 Q1 | 598 Million INR | 10.74% |
| 2012 FY | 2.63 Billion INR | -7.74% |
| 2011 Q2 | 735 Million INR | 0.0% |
| 2011 Q4 | 539.99 Million INR | -33.42% |
| 2011 Q3 | 811 Million INR | 10.34% |
| 2011 FY | 2.85 Billion INR | 20.41% |
| 2010 FY | 2.36 Billion INR | -2.02% |
| 2009 FY | 2.41 Billion INR | -7.21% |
| 2008 FY | 2.6 Billion INR | 16.82% |
| 2007 FY | 2.23 Billion INR | -10.99% |
| 2006 FY | 2.5 Billion INR | 5.87% |
| 2005 FY | 2.36 Billion INR | 7.84% |
| 2004 FY | 2.19 Billion INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Abbott India Limited | 13.79 Billion INR | 11.606% |
| Cipla Limited | 105.7 Billion INR | 88.466% |
| Gland Pharma Limited | 16.45 Billion INR | 25.886% |
| GlaxoSmithKline Pharmaceuticals Limited | 13.6 Billion INR | 10.359% |
| Kopran Limited | 675.44 Million INR | -1705.175% |
| Marksans Pharma Limited | 7.79 Billion INR | -56.489% |
| NGL Fine-Chem Limited | 416.27 Million INR | -2829.101% |
| Pfizer Limited | 9.61 Billion INR | -26.856% |
| SMS Pharmaceuticals Limited | 1.34 Billion INR | -809.827% |
| TTK Healthcare Limited | 249.89 Million INR | -4779.347% |